Latest news about Bitcoin and all cryptocurrencies. Your daily crypto news habit.
Pharmaceutical companies could soon use blockchain for securities trading, Verseon predicts.
U.S. pharmaceutical company Verseon has become the latest medical organization to experiment in blockchain technology, it confirmed in a press release Tuesday, September 18.
Verseonās main product is its proprietary physics-based drug discovery platform. The company was established in 2002 and it now trades on the London Stock Exchange, boasting a market cap of Ā£211 million ($277 million).
Part of a growing trend among major pharmaceutical players to leverage blockchainās data and security benefits, the companyās subsidiary BlockRules will facilitate what it describes as technology which āsupports the sale, launch, and trading of securities on a public blockchain.ā
This, the release explains, āpermits fully regulated, secure, and transparent support of securities, including decentralized tradingā and will assist other pharmaceuticals players to overhaul their funding and development strategy.
āBy democratizing investment access with blockchain technology, we will change the way new medicines and other life-science innovations are funded and how the resulting proceeds are shared,ā Verseon CEO Adityo Prakash commented.
The move marks a continuation of the innovation which is ongoing in the wider health industry this year.
As Cointelegraph reported, multiple actors have identified blockchainās ability to safeguard previously costly and inefficient processes such as supply chains and ensuring drugs are not tampered with.
Individual setups are also appearing beyond big business, such as in Taiwan, where earlier this month one hospital debuted a blockchain record-keeping system for sensitive patient data.
Disclaimer
The views and opinions expressed in this article are solely those of the authors and do not reflect the views of Bitcoin Insider. Every investment and trading move involves risk - this is especially true for cryptocurrencies given their volatility. We strongly advise our readers to conduct their own research when making a decision.